Home / Business / Short Call at News Buzzer: QUALCOMM (NASDAQ:QCOM), Geron (NASDAQ:GERN), SORL Auto Parts (NASDAQ:SORL)

Short Call at News Buzzer: QUALCOMM (NASDAQ:QCOM), Geron (NASDAQ:GERN), SORL Auto Parts (NASDAQ:SORL)

QUALCOMM Incorporated (NASDAQ:QCOM) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with 2.86% to $62.25. Qualcomm Inc. (QCOM) reported the opening of Qualcomm Communication Technologies (Shanghai) Co. Ltd., a semiconductor test facility in the Waigaoqiao or WGQ free-trade zone in Shanghai, and its first foray into providing manufacturing services for semiconductors. By working with Amkor Technology Inc., the new firm will combine Amkor’s test services experience and state of the art cleanroom facilities with Qualcomm Technologies’ industry leadership in cutting-edge product engineering and development. The Shanghai-based facility is set to start operations on October 18, 2016. The share price of QCOM attracts active investors, as stock price of week volatility recorded 2.09%. The stock is going forward to its 52-week low with 51.46% and lagging behind from its 52-week high price with -2.28%.

Geron Corporation (NASDAQ:GERN) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -19.58% to close at $2.30 with the total traded volume of 12.88 Million shares. Geron Corp. (GERN) provided updates on the clinical trials being conducted by Janssen Research & Development, LLC, of the telomerase inhibitor imetelstat. Planned internal reviews of initial data from both trials have been completed by Janssen, and both trials are continuing in order to evaluate additional and more mature data.

IMbark (NCT02426086) was originally deinked as a Phase 2 clinical trial to evaluate two dose levels of imetelstat in about 200 patients with Intermediate-2 or High risk myelofibrosis (MF) who have relapsed following or are refractory to previous treatment with a JAK inhibitor. The co-primary efficacy endpoints for the trial are spleen response rate and symptom response rate at 24 weeks. To date, over 90 patients have been enrolled in the trial across both dosing arms. The firm has institutional ownership of 38.40%, while insider ownership included 0.50%. Its price to sales ratio ended at 10.69. GERN attains analyst recommendation of 2.20 with week performance of -16.36%.

SORL Auto Parts, Inc. (NASDAQ:SORL) [Trend Analysis] increased reacts as active mover, shares an advance 23.69% to traded at $3.55 and the percentage gap among open changing to regular change was 3.14%. The firm’s current ratio calculated as 1.90 for the most recent quarter. The firm past twelve months price to sales ratio was 0.29 and price to cash ratio remained 5.93. As far as the returns are concern, the return on equity was recorded as 8.50% and return on investment was 5.60% while its return on asset stayed at 5.20%. The firm has total debt to equity ratio measured as 0.20.


About Aaron Smithies

Aaron Smithies has a wide look on current monetary and financial events. He is an editor and a writer. His views; At Streetwise Report, we think the best opportunities arise from a complete understanding of all investing disciplines in order to identify the most attractive stocks at any given time. Interests: Biotech, Finical markets, Dividend stock ideas & income, Energy stocks, Consumer goods stocks

Check Also

Stocks Retreat on New Development: Deutsche Bank (NYSE:DB), Ingram Micro (NYSE:IM)

Shares of Deutsche Bank AG (NYSE:DB) [Trend Analysis] swings enthusiastically in regular trading session, it a decrease …

Leave a Reply

Your email address will not be published. Required fields are marked *